Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838513 | 0.88 | RAB9A (0.62) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL2838509 | 0.88 | RAB9A (0.62) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL2829791 | 0.87 | RAB9A (0.65) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL2141599 | 0.87 | RAB9A (0.60) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL1513053 | 0.87 | RAB9A (0.60) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL9049845 | 0.87 | MAPT (0.67) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL15359481 | 0.87 | RAB9A (0.60) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL348057 | 0.87 | RAB9A (0.60) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL9380792 | 0.87 | MAPT (0.57) | RAB9ANPC1MAPTALDH1A1KMT2A | |
| SCHEMBL2435873 | 0.85 | MAPT (0.69) | RAB9ANPC1MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | disclosed |
| WO-2018132326-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2018-07-19 | — | — | WO | disclosed |
| EP-2778156-B1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | ASTRAZENECA AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| EP-2778156-A1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | AstraZeneca AB (Publ) (SE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013149362-A1 | 1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1664063-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026177-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-0402246-B1 | Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation | ROUSSEL UCLAF (FR) | 1994-08-24 | — | — | EP | disclosed |
| CN-1048386-A | Novel thiazole base alkoxy acrylic ester, they the preparation method, do the purposes of mycocide and prepare the intermediate of this compounds | ROUSSEL UCLAF (FR) | 1991-01-09 | — | — | CN | disclosed |
| EP-0402246-A1 | Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation | ROUSSEL-UCLAF (FR) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | RAB9A 2065/4885NPC1 1129/4885MAPT 2430/4885 |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | TNF, GCDH, LITAF | RAB9A 3317/4885NPC1 2990/4885MAPT 1060/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | RAB9A 2496/4885NPC1 1516/4885MAPT 4270/4885 |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | HRH4, HRH2, HRH3 | RAB9A 787/4885NPC1 2482/4885MAPT 4500/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | RAB9A 2326/4885NPC1 2863/4885MAPT 1229/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | RAB9A 2424/4885NPC1 3563/4885MAPT 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.